Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > News > Dose-Dense Chemotherapy Plus Bevacizumab Followed by Nab-Paclitaxel Appears Cardiac Safe in Early-Stage Breast Cancer: Presented at SABCS

December 16th, 2008

Dose-Dense Chemotherapy Plus Bevacizumab Followed by Nab-Paclitaxel Appears Cardiac Safe in Early-Stage Breast Cancer: Presented at SABCS

Abstract:
A dose-dense anthracycline-based therapy that includes bevacizumab followed by nanoparticle albumin-bound paclitaxel (nab-paclitaxel) appears to avoid serious cardiac toxicity in its role as adjuvant treatment for early-stage breast cancer, researchers reported at the 31st Annual San Antonio Breast Cancer Symposium (SABCS).

Heather McArthur, MD, Memorial Sloan-Kettering Cancer Center, New York, New York and colleagues enrolled 80 women with early-stage breast cancer into a trial in which patients were treated with bevacizumab 10 mg/kg administered intravenously every 2 weeks for 8 cycles, concurrently with doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 2 weeks for 4 cycles, and then nab-paclitaxel 260 mg/m2 every 2 weeks for 4 cycles. After 8 cycles, for the rest of 1 year, bevacizumab was administered at a dose of 15 mg/kg every 3 weeks. Pegfilgrastim was administered on day 2 of each chemotherapy cycle.

Source:
docguide.com

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

East China University of Science and Technology Purchases Nanonex Advanced Nanoimprint Tool NX-B200 July 30th, 2014

Watching Schrödinger's cat die (or come to life): Steering quantum evolution & using probes to conduct continuous error correction in quantum computers July 30th, 2014

From Narrow to Broad July 30th, 2014

FLAG-ERA and TNT2014 join efforts: Graphene Networking at its higher level in Barcelona: Encourage the participation in a joint transnational call July 30th, 2014

Nanomedicine

New imaging agent provides better picture of the gut July 30th, 2014

Zenosense, Inc. July 29th, 2014

Optimum inertial design for self-propulsion: A new study investigates the effects of small but finite inertia on the propulsion of micro and nano-scale swimming machines July 29th, 2014

FEI adds Phase Plate Technology and Titan Halo TEM to its Structural Biology Product Portfolio: New solutions provide the high-quality imaging and contrast necessary to analyze the 3D structure of molecules and molecular complexes July 28th, 2014

Announcements

University of Manchester selects Anasys AFM-IR for coatings and corrosion research July 30th, 2014

Nature inspires a greener way to make colorful plastics July 30th, 2014

Analytical solutions from Malvern Instruments support University of Wisconsin-Milwaukee researchers in understanding environmental effects of nanomaterials July 30th, 2014

FEI Unveils New Solutions for Faster Time-to-Analysis in Metals Research July 30th, 2014

Events/Classes

FLAG-ERA and TNT2014 join efforts: Graphene Networking at its higher level in Barcelona: Encourage the participation in a joint transnational call July 30th, 2014

FEI Unveils New Solutions for Faster Time-to-Analysis in Metals Research July 30th, 2014

WITec to host the 11th Confocal Raman Imaging Symposium from September 29th - October 1st in Ulm, Germany July 28th, 2014

FEI adds Phase Plate Technology and Titan Halo TEM to its Structural Biology Product Portfolio: New solutions provide the high-quality imaging and contrast necessary to analyze the 3D structure of molecules and molecular complexes July 28th, 2014

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE